Table 3 General characteristics of Analytical studies
Author, year, Reference | Country | Sample size | Variables | Mean ± SD drug group | Mean ± SD placebo group | Drug | Quality | |||
|---|---|---|---|---|---|---|---|---|---|---|
Placebo group | Drug group | Before | After | Before | After | |||||
Immunoglobulin or plasma exchange | ||||||||||
 Barth, 2011, [31] | Canada | 41 | – | QMGS | 14.26 ± 4.0 | 10.96 ± 3.5 | – | – | IVIG | High |
 Gajdos-1, 1997, [99] | France | 46 | – | Anti-AchR ab level, nmol/L | 25 ± 65 | 17 ± 40 | – | – | IVIG | Medium |
 Zinman, 2007, [100] | Canada | 24 | 27 | QMGS | 12.3 ± 4.89 | 9.76 ± 4.0 | 12.5 ± 5.49 | 11.61 ± 4.5 | IVIG | High |
SFEMG | 85.2 ± 50.0 | – | 91.6 ± 37.9 | – | ||||||
 Wolfe, 2002, [101] | USA | 6 | 9 | QMGS | 8.5 ± 1.8 | 8.5 ± 3.8 | 11.3 ± 5.6 | 9.7 ± 2.7 | IVIG | High |
SFEMG | 66.9 ± 21.0 | 56.6 ± 17.5 | 115 ± 84.2 | 94.1 ± 10.2 | ||||||
MG-ADL | 5.3 ± 3.8 | 5.0 ± 2.0 | 6.0 ± 3.8 | 3.4 ± 2.4 | ||||||
 Gajdos-2, 2005, [30] | France | 81 | 87 | Anti-AchR ab level, nmol/L | 12.0 ± 2.5 | 11.21 ± 14.02 | 10.0 ± 2.8 | 9.35 ± 15.07 | IVIG | High |
 Gamez, 2019, [102] | Spain | 25 | 22 | QMGS | 6.1 ± 3.8 | 5.2 ± 2.4 | 6.6 ± 3.5 | 7.1 ± 3.5 | IVIG | High |
Anti-AchR ab level, nmol/L | 14.4 ± 8.0 | 16.3 ± 7.4 | 11.3 ± 8.5 | 14.4 ± 8.5 | ||||||
 Barnett, 2013, [103] | USA | 26 | 25 | QMGS | 12.2 ± 4.9 | 11.68 ± 4.0 | 12.4 ± 5.5 | 12.25 ± 3.5 | IVIG | High |
 Zinman, 2008, [104] | Canada | 26 | 26 | QMGS | 12.5 ± 5.5 | 11.5 ± 4.1 | 12.3 ± 4.9 | 14.0 ± 0.71 | IVIG | High |
 Katzberg, 2014, [105] | Netherlands | 24 | 27 | QMGS | 12.3 ± 3.5 | 10.22 ± 3.5 | 12.5 ± 1.9 | 12.09 ± 1.9 | IVIG | High |
SFEMG | 85.2 ± 3.0 | 76.3 ± 3.0 | 91.6 ± 4.1 | 86.3 ± 1.5 | ||||||
 Jacob, 2020, [106] | Japan | 9 | 9 | QMGS | 18.1 ± 5.84 | 14.0 ± 3.6 | 18.2 ± 5.49 | 16.9 ± 2.8 | Eculizumab | High |
|  |  | MG-ADL | 10.9 ± 3.37 | 5.6 ± 3.2 | 9.7 ± 2.4 | 7.6 ± 2.8 | ||||
 Gajdos-3, 2008, [107] | France | 87 | 85 | QMGS | 3.9 ± 1.1 | 1.36 ± 0.9 | 4.2 ± 0.70 | 3.31 ± 1.2 | IVIG | High |
 Katzberg-2, 2012, [32] | Canada | 24 | 81 | QMGS | 12.6 ± 3.6 | 12.4 ± 4.2 | 14.9 ± 3.2 | 14.4 ± 4.5 | IVIG | Medium |
Anti-AchR ab level, μmol/L | – | 166.2 ± 12.3 | – | 209.1 ± 11.6 | ||||||
SFEMG | 86.6 ± 7.7 | 85.2 ± 6.5 | 122.5 ± 7.5 | 117.2 ± 6.3 | ||||||
 Howard, 2019, [108] | Netherlands | 12 | 12 | QMGS | 11.8 ± 5.4 | 8.9 ± 3.8 | 14.5 ± 6.3 | 12.4 ± 4.6 | Efgartigimod | High |
SFEMG | 8.0 ± 2.2 | 3.6 ± 1.6 | 8.0 ± 3.0 | 5.9 ± 3.1 | ||||||
Corticosteroids | ||||||||||
 Benatar, 2016, [109] | USA | 6 | 5 | QMGS | 6.0 ± 0.2 | 3.75 ± 0.9 | 6.5 ± 1.8 | 6.45 ± 1.3 | Prednisone | High |
 Howard, 1976, [110] | USA | 20 | 21 | QMGS | 8.18 ± 0.63 | 8.15 ± 0.32 | 7.97 ± 0.91 | 8.04 ± 0.47 | Prednisone | Medium |
 Lindberg, 1998, [111] | USA | 10 | 9 | Anti-AchR ab level, μmol/L | 354 ± 290 | – | 401 ± 264 | – | Methylprednisolone | Medium |
Mycophenolate | ||||||||||
 Sanders, 2008, [112] | USA | 88 | 88 | QMGS | 11.3 ± 1.2 | 7.3 ± 1.0 | 11.2 ± 1.3 | 7.9 ± 1.4 | Mycophenolate | High |
|  |  | MG-ADL | 5.14 ± 0.77 | 2.71 ± 0.81 | 4.55 ± 0.79 | 2.74 ± 0.74 | ||||
 Meriggioli, 2003, [21] | USA | 7 | 7 | QMGS | 15.86 ± 15.2 | 13.0 ± 10.8 | 16.71 ± 12.3 | 16.43 ± 11.2 | Mycophenolate | High |
Anti-AchR ab level, nmol/L | 9.3 ± 2.3 | 3.32 ± 0.62 | 4.39 ± 0.9 | 3.81 ± 1.3 | ||||||
SFEMG | 71.54 ± 11.3 | 60.52 ± 13.1 | 70.0 ± 13.2 | 69.26 ± 12.5 | ||||||
 Wolfe, 2008, [113] | USA | 40 | 40 | QMGS | 12.9 ± 5.1 | 8.42 ± 5.1 | – | – | Mycophenolate | Medium |
MG-ADL | 6.9 ± 3.1 | 3.3 ± 3.3 | 7.2 ± 3.4 | 4.4 ± 3.7 | ||||||
Group, 2008, [114] | USA | 41 | 39 | QMGS | 13.3 ± 5.6 | 8.9 ± 5.1 | 12.5 ± 4.5 | 8.9 ± 5.0 | Mycophenolate | High |
Anti-AchR ab level, nmol/L | 13.6 ± 11.3 | 8.3 ± 9.5 | 23.0 ± 13.2 | 16.9 ± 10.8 | ||||||
MG-ADL | 6.9 ± 3.1 | 3.3 ± 3.3 | 7.2 ± 3.4 | 4.4 ± 3.7 | ||||||